GCP
XLO icon

GSA Capital Partners’s Xilio Therapeutics XLO Stock Holding History

GSA Capital Partners’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$143K Buy
16,946
+6,377
+60% +$52.2K 0.01% 1517
2025
Q4 		$95K Buy
+10,569
New +$111K 0.01% 1535

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GSA Capital Partners's XLO Position: Q1 2026 in Review

GSA Capital Partners increased its Xilio Therapeutics (XLO) stake by 60% in Q1 2026, buying an estimated $52.2K and bringing the position to 16,946 shares worth $143K. The position accounts for 0.01% of the portfolio, ranked #1517.

GSA Capital Partners first reported a position in XLO in Q4 2025 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • GSA Capital Partners held 16,946 shares of Xilio Therapeutics worth $143K as of Q1 2026.
  • GSA Capital Partners bought 6,377 Xilio Therapeutics shares in Q1 2026, an estimated $52.2K.
  • Xilio Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1517 holding.
  • GSA Capital Partners first reported a position in Xilio Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.